**Name of Journal: *World Journal of Hepatology***

**ESPS Manuscript NO: 28178**

**Manuscript Type: Original Article**

***Case Control Study***

**Pancreatic hyperechogenicity associated with hypoadiponectinemia and insulin resistance: A Japanese population study**

Makino N *et al.* Pancreatic hyperechogenicity and hypoadiponectinemia

**Naohiko Makino, Nakao Shirahata, Teiichiro Honda, Yoshiaki Ando, Akiko Matsuda, Yushi Ikeda, Miho Ito, Yuko Nishise, Takafumi Saito, Yoshiyuki Ueno and Sumio Kawata**

**Naohiko Makino, Nakao Shirahata, Teiichiro Honda, Yoshiaki Ando, Akiko Matsuda, Yushi Ikeda, Miho Ito, Yuko Nishise, Takafumi Saito, Yoshiyuki Ueno,** Department of Gastroenterology, Faculty of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan

**Sumio Kawata,** Department of Internal Medicine, Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokutanji-cho, Nishinomiya, Hyogo 662-0918, Japan

**Author contributions**: Makino N and Kawata S designed the research; Shirahata N, Honda T, Ando Y, Matsuda A, Ikeda Y, Ito M, Nishise Y, Saito T and Ueno Y performed the research; Makino N wrote the paper.

**Institutional review board statement:** The study was reviewed and approved by the Ethics Committee of Yamagata University Faculty of Medicine.

**Informed consent statement:** All participants provided informed written consent prior to study enrollment.

**Conflict-of-interest** **statement:** The authors declare that they have no conflict of interest.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to:** **Naohiko Makino, MD, PhD, Associate Professor,** Department of Gastroenterology, Faculty of Medicine, Yamagata University, 2-2-2 Iida-Nishi, Yamagata 990-9585, Japan. namakino@med.id.yamagata-u.ac.jp

**Telephone:** +81-23-6285307

**Fax:** +81-23-6285311

**Received:** June 27, 2016

**Peer-review started:** June 28, 2016

**First decision:** August 22, 2016

**Revised:** September 8, 2016

**Accepted:** October 17, 2016

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To examine the relationship between pancreatic hyperechogenicity and risk factors for metabolic syndrome.

***METHODS***

A general population-based survey of lifestyle-related diseases was conducted from 2005 to 2006 in Japan. The study involved 551 participants older than 40 year of age. Data for 472 non-diabetic adults were included in the analysis. The measures included the demographic factors, blood parameters, results of a 75 g oral glucose tolerance test, and abdominal ultrasonography. The echogenicity of the pancreas and liver was compared, and then the subjects were separated into two groups: cases with pancreatic hyperechogenicity (*n* = 208) and cases without (controls, *n* = 264). The differences between both groups were compared using an unpaired *t*- test or Fisher’s exact test. Multiple logistic regression analysis was used to determine the relationship between the pancreatic hyperechogenicity and clinical and biochemical parameters.

***RESULTS***

Subjects with pancreatic hyperechogenicity had decreased serum adiponectin concentration compared to control subjects [8.9 (6.5; 12.8) *vs* 11.1 (7.8; 15.9), *P* < 0.001] and more frequently exhibited features of metabolic syndrome. Logistic regression analysis showed that the following variables were significantly and independently associated with pancreatic hyperechogenicity: presence of hypoadiponectinemia, increased body mass index (BMI), higher homeostasis model assessment of insulin resistance (HOMA-IR) score, and presence of fatty liver. Similar associations were also observed in subjects with pancreatic hyperechogenicity without fatty liver. Multivariate association analysis of data from participants without fatty liver showed that hypoadiponectinemia was significantly associated with pancreatic hyperechogenicity (OR = 0.93, 95%CI: 0.90 – 0.97, *P* < 0.001). This association was independent of other confounding variables. Additionally, an increased BMI and higher HOMA-IR score were significantly associated with pancreatic hyperechogenicity.

***CONCLUSION***

Pancreatic hyperechogenicity is independently associated with increased BMI, insulin resistance, and hypoadiponectinemia in the general population.

**Key words:** Pancreatic hyperechogenicity; Metabolic syndrome; Obesity; Adiponectin; The Takahata study

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Pancreatic hyperechogenicity is related to aging. Several recent studies have reported that hepatic steatosis and increased BMI are predictors of a hyperechogenic pancreas. In the present study, fatty liver was also significantly associated with pancreatic hyperechogenicity. We performed additional analyses excluding participants with fatty liver in order to account for the effect of this condition. Our analyses showed that an increased BMI, higher HOMA-IR score, and decreased adiponectin were also significantly associated with pancreatic hyperechogenicity.

Makino N, Shirahata N, Honda T, Ando Y, Matsuda A, Ikeda Y, Ito M, Nishise Y, Saito T, Ueno Y, Kawata S. Pancreatic hyperechogenicity associated with hypoadiponectinemia and insulin resistance: A Japanese population study. *World J Hepatol* 2016; In press

**INTRODUCTION**

Pancreatic hyperechogenicity may be related to the aging process[1-3]. Previous studies have reported that increased echogenicity of the pancreas is associated with pancreatic lipomatosis[4,5]. Additionally, recent ultrasound studies have demonstrated pancreatic hyperechogenicity is correlated with obesity, hepatic steatosis[6,7], and insulin resistance[8]. To our knowledge, there are a limited number of reports examining the relationship between pancreatic hyperechogenicity and lifestyle-related risk factors.

Recent studies have demonstrated that adipose tissue not only stores fat but also functions as an endocrine organ by producing various adipocytokines such as adiponectin. Adiponectin is a peptide hormone that plays a key role in the development of insulin resistance associated with metabolic syndrome[9]. Adiponectin levels are correlated directly with insulin sensitivity and are decreased in obese individuals and patients with type 2 diabetes[10,11]. Recent studies have shown that there is an association between low concentrations of adiponectin and cancer development[12,13]. However, no report has examined the relationship between adiponectin concentration and pancreatic hyperechogenicity.

The aim of the present study was to examine the associations between pancreatic hyperechogenicity and risk factors for metabolic syndrome, including adiponectin concentration, in the general Japanese population.

**MATERIALS AND METHODS**

***Study population***

The study was part of an ongoing molecular epidemiological project utilizing the regional characteristics of the 21st Century Centers of Excellence program in Japan, which has been previously described[14]. The surveyed population was the entire population of adults aged over 40 year in the town of Takahata, Yamagata prefecture, located in northeastern Japan. There were 551 participants enrolled in the study between 2005 and 2006. All participants received a physical examination, blood tests, a 75-g oral glucose tolerance test (OGTT), and abdominal ultrasonography (US). We excluded 79 of the 551 participants for the following reasons: poor US images of the pancreas (43 individuals); blood samples collected in a non-fasting state (27 individuals); or OGTT-diagnosed diabetes mellitus based on the American Diabetes Association criteria (9 individuals)[15]. Exclusion criteria included a history of diabetes or pancreatic disease. However, no participants met the exclusion criteria. The data collected from 472 subjects (201 males and 271 females) were included in the final analysis.

***Measurements***

We obtained information on current medication and lifestyle-related characteristics from all participants using a questionnaire. Trained study staff measured height, weight and systolic and diastolic blood pressure (BP) using standard methods. Body mass index (BMI) was calculated as weight (in kilograms) divided by height (in meters squared). Insulin resistance was evaluated using the homeostasis model assessment of insulin resistance (HOMA-IR) method with the following equation: HOMA-IR = fasting insulin (μU/mL) × fasting glucose (mg/dL)/405. Venous blood was drawn the morning after an overnight fast. The serum and plasma were separated immediately and stored at -80 °C until analysis. The serum adiponectin concentrations were measured by an enzyme-linked immunosorbent assay as described previously[9]. The other biochemical blood parameters were determined by standard laboratory procedures in the General Laboratory of BML, Inc. (Saitama, Japan). All laboratory personnel were blinded to the status of the samples.

All participants underwent US and an OGTT during a single visit at the research center and within 2 mo of the physical examination and initial blood collection. Blood samples were obtained to determine plasma glucose in the basal period and 120 min after an oral glucose load in the morning following an overnight fast.

The participants fasted overnight for the US study, and the scans were performed by one of four experienced operators using either a Toshiba NemioTM scanner or an Aloka SSD-3500 scanner with a 3.5-MHz convex transducer. The participants were scanned while lying supine. The images were recorded on a standard computer hard disk drive. The recorded images were analyzed and judged simultaneously by four experienced physicians blinded to the details of the subjects, as described in a previous report[5]. The echogenicity of the pancreatic body was compared with the liver. The subjects were separated into cases with pancreatic echogenicity higher than hepatic echogenicity (*n* = 208) and controls whose pancreatic echogenicity was equal to or lower than the liver (*n* = 264). The presence of fatty liver was defined as a US pattern consistent with evidence of increased ultrasonographic contrast between the hepatic and renal parenchyma, vessel blurring, and narrowing of the lumen of the hepatic veins. We used these criteria to divide the subjects into cases with (*n* = 206) or without (*n* = 266) fatty liver.

***Statistical analysis***

The distribution of the continuous variables was assessed for normality. If a normal distribution was evident, then the data were expressed as the means ± standard deviation (SD). The data with a non-normal distribution were log-transformed for analysis and expressed as the median with 25th/75th percentiles. The case and control groups were compared using the unpaired *t* test or Fisher’s exact test. The relationship between pancreatic hyperechogenicity and clinical and biochemical parameters was determined using multiple logistic regression analyses with the backward elimination method. The odds ratio (OR) and 95%CI were then calculated.

The parameters in the multiple logistic regression analysis were categorized using the following cutoff values: BMI (< 25 kg/m2, ≥ 25 kg/m2), systolic BP (< 130 mmHg, ≥ 130 mmHg), diastolic BP (< 85 mmHg, ≥ 85 mmHg), fasting plasma glucose (< 110 mg/dL, ≥ 110 mg/dL), HOMA-IR score (< 2.0, ≥ 2.0), high-density lipoprotein (HDL) cholesterol (< 40 mg/dL, ≥ 40 mg/dL), triglyceride (< 150 mg/dL, ≥ 150 mg/dL), glutamic pyruvic transaminase (GPT) (< 35 IU/l, ≥ 35 IU/L), pre-load plasma glucose in the OGTT (< 110 mg/dl, ≥ 110 mg/dL) and post-load 2-hour (2-h) plasma glucose in the OGTT (< 140 mg/dL, ≥ 140 mg/dL). The median values for serum insulin and pancreatic isoamylase were used as the cutoff points. Serum adiponectin was analyzed as a continuous variable. All data were analyzed using SPSS software (version 15.0, SPSS Inc., Chicago, IL, United States). All differences with *P* < 0.05 were considered statistically significant. The statistical methods of this study were reviewed by Yuko Nishise from the Faculty of Medicine, Yamagata University.

**RESULTS**

The baseline clinical and biochemical data for the cases and controls are shown in Table 1. The serum adiponectin levels were markedly lower in the cases than in the controls [8.9 (6.5-12.8) *vs* 11.1 (7.8-15.9), *P* < 0.001]. In addition, there were significant differences between the cases and controls for the following variables: age, presence of fatty liver, weight, BMI, systolic BP, diastolic BP, serum insulin, fasting plasma glucose, HOMA-IR score, HDL cholesterol, total cholesterol, triglyceride, pancreatic isoamylase, GPT, preload plasma glucose in the OGTT, and 2-h plasma glucose.

Each parameter was dichotomized according to the cutoff points to further explore the relationship between pancreatic hyperechogenicity and other parameters. We then conducted multiple logistic regression analyses with the backward elimination method.

We first used an age-adjusted model to exclude the influence of aging. The results indicate that there was a significant negative association between decreased adiponectin levels and pancreatic hyperechogenicity (OR = 0.92, 95%CI: 0.88 - 0.95, *P* < 0.001). In addition, the presence of fatty liver, higher values of BMI, systolic BP, diastolic BP, serum insulin, HOMA-IR score, 2-h plasma glucose and lower pancreatic isoamylase levels were significantly associated with pancreatic hyperechogenicity (Table 2).

We next performed the analysis after adjustment for age, presence of fatty liver, BMI, systolic and diastolic BP, adiponectin, serum insulin, HOMA-IR, triglyceride, pancreatic isoamylase, GPT, and 2-h plasma glucose. The analysis showed that hypoadiponectinemia was significantly associated with pancreatic hyperechogenicity (OR = 0.9, 95%CI: 0.91 – 0.98, *P* = 0.004), independent of the other confounding variables. The presence of fatty liver, increased BMI, and higher HOMA-IR score were also significantly associated with pancreatic hyperechogenicity. In addition, decreased pancreatic isoamylase showed a weak relationship with pancreatic hyperechogenicity (Table 2).

We then performed further analyses to exclude the influence of fatty liver. The baseline clinical and biochemical data for cases and controls without fatty liver are shown in Table 3. The serum adiponectin levels were lower in cases than in controls [10.3 (7.6-14.6) *vs* 12.0 (8.6-17.0), *P* = 0.022]. Furthermore, there were significant differences between cases and controls for the following parameters: age, weight, BMI, serum insulin, fasting plasma glucose, HOMA-IR score, HDL cholesterol, triglycerides, and preload plasma glucose in the OGTT.

We next performed multivariate association analyses of data from participants without fatty liver. The multivariate analysis showed that hypoadiponectinemia was significantly associated with pancreatic hyperechogenicity (OR = 0.93, 95%CI: 0.90 – 0.97, *P* <0.001), independent of the other confounding variables. Additionally, an increased BMI and higher HOMA-IR score were also significantly associated with pancreatic hyperechogenicity (Table 4).

**DISCUSSION**

Studies examining digestive organ disease and altered secretion of adipocytokines caused by metabolic syndrome will improve our understanding of the mechanisms involved in pathophysiological conditions. It is possible that such investigations might lead to the development of preventive measures for diseases linked to metabolic syndrome.

Pancreatic hyperechogenicity is thought to be related to the aging process[1-3]. Our data showed that several features of metabolic syndrome, such as higher BMI, increased HOMA-IR score, and hypoadiponectinemia, were also independently associated with pancreatic hyperechogenicity.

This is the first study conducted in a general population that investigated the relationship between pancreatic hyperechogenicity and risk factors of metabolic syndrome, such as insulin resistance and serum adiponectin concentration. The main study findings were (1) that serum adiponectin concentrations were markedly lower in subjects with pancreatic hyperechogenicity than in controls [8.9 (6.5- 12.8) *vs* 11.1 (7.8-15.9), *P* < 0.001]; and (2) that decreased adiponectin levels were associated independently with pancreatic hyperechogenicity (OR = 0.9, 95%CI: 0.91 – 0.98, *P* = 0.004). Adiponectin is produced by adipose tissue, and a low adiponectin concentration is considered to be a key factor in the development of insulin resistance underlying metabolic syndrome[9-11].

Several studies have reported that increased echogenicity of the pancreas is related to lipomatosis of the pancreatic parenchyma[4,5]. Pancreatic lipomatosis is the most common histological change in the pancreas associated with age, obesity, and insulin resistance[6-8,16-19]. Recently, Raeder *et al*[5] evaluated the pancreatic fat content using US and magnetic resonance imaging and showed that pancreatic lipomatosis may reflect early events involved in the pathogenesis of diabetes and exocrine pancreatic dysfunction in non-diabetic children with mutations in carboxyl-ester lipase. In addition, Tushuizen and co-workers[20] measured the pancreatic fat content using proton magnetic resonance spectroscopy and found that pancreatic fat was inversely associated with β-cell function parameters in non-diabetic men. However, there was no association in their diabetic counterparts. The authors suggested that pancreatic fat content may contribute to β-cell dysfunction[20]. In our logistic regression analysis, we adjusted for age and pancreatic hyperechogenicity, which is a potential marker of lipomatosis. We found that these parameters were associated with higher serum insulin, HOMA-IR, and 2-h plasma glucose levels in the OGTT. There was no association with fasting and preload plasma glucose concentrations in the OGTT (Table 2). It is possible that pancreatic hyperechogenicity with insulin resistance precedes the development of diabetes in the non-diabetic general population. Thus, further large-scale prospective studies are necessary to investigate whether pancreatic hyperechogenicity is an early pathological event in the diabetes disease process.

Several recent studies have reported that hepatic steatosis and increased BMI are predictors of a hyperechogenic pancreas[6,7]. In the present study, fatty liver was also significantly associated with pancreatic hyperechogenicity (OR = 1.77, 95%CI: 1.15 – 2.72, *P* = 0.009) (Table 2). Therefore, we performed additional analyses excluding participants with fatty liver in order to account for the effect of this condition in our results. The adjusted analysis showed that increased BMI, higher HOMA-IR score, and decreased adiponectin were also significantly associated with pancreatic hyperechogenicity (Table 4). This is the first study investigating the relationship between pancreatic hyperechogenicity and risk factors for metabolic syndrome by excluding the influence of fatty liver.

In this study, we used a simple and traditional method of assessing the severity of pancreatic hyperechogenicity, which was the comparison of echogenicity between the pancreatic body and the liver. However, this approach can potentially result in misdiagnosis of pancreatic hyperechogenicity if the extent of fatty liver is severe. We also performed additional analyses to exclude the influence of fatty liver. As shown in Tables 2 and 4, the results of our analyses that either included or excluded fatty liver, respectively, were similar and both showed increased BMI, higher HOMA-IR scores, and decreased adiponectin levels. However, our study had a limitation: no histological confirmation of pancreatic fat was possible.

There may be unknown factors that may cause the histological changes associated with obesity in addition to fat accumulation, fibrosis and functional changes in the exocrine pancreas. We recently demonstrated that intra-lobular fat accumulates in exocrine pancreatic tissue and that lipid droplets in acinar cells increase in Zucker diabetic fatty rats, which is an animal model of type 2 diabetes caused by the chronic intake of a high-fat diet. These conditions appear cause acinar cell injury and fibrosis[21]. Thus, additional clinical and experimental studies of the interrelationships between diabetes, metabolic syndrome and pancreatic injury should be conducted to clarify the pathogenesis of “non-alcoholic fatty pancreatic disease”.

In conclusion, our study of a non-diabetic general population showed that pancreatic hyperechogenicity was independently associated with increased BMI, insulin resistance and hypoadiponectinemia.

**ACKNOWLEDGMENTS**

We are grateful to all the participants and volunteers who enrolled in this study. We also thank Ms. Miho Ishii and Dr. Mitsuru Emi for helpful advice.

**COMMENTS**

***Background***

Pancreatic hyperechogenicity is thought to be related to the aging process. However, little is known about the association between pancreatic hyperechogenicity and other life-style related risk factors.

***Research frontiers***

Prior studies have reported that increased echogenicity of the pancreas is associated with pancreatic lipomatosis. Recent ultrasound studies have shown that pancreatic hyperechogenicity is correlated with obesity, hepatic steatosis, and insulin resistance.

***Innovations and breakthroughs***

This is the first study investigating the relationship between pancreatic hyperechogenicity and risk factors for metabolic syndrome by excluding the influence of fatty liver.

***Applications***

Pancreatic hyperechogenicity is independently associated with increased BMI, insulin resistance, and hypoadiponectinemia in the general population. Pancreatic hyperechogenicity could be a useful marker of the metabolic syndrome.

***Peer-review***

Accept the manuscript for publication without significant corrections.

**REFERENCES**

1 **Worthen NJ**, Beabeau D. Normal pancreatic echogenicity: relation to age and body fat. *AJR Am J Roentgenol* 1982; **139**: 1095-1098 [PMID: 6983252 DOI: 10.2214/ajr.139.6.1095]

2 **Glaser J**, Stienecker K. Pancreas and aging: a study using ultrasonography. *Gerontology* 2000; **46**: 93-96 [PMID: 10671806 DOI: 10.1159/000022141]

3 **Silva ME**, Vezozzo DP, Ursich MJ, Rocha DM, Cerri GG, Wajchenberg BL. Ultrasonographic abnormalities of the pancreas in IDDM and NIDDM patients. *Diabetes Care* 1993; **16**: 1296-1297 [PMID: 8404436 DOI: 10.2337/diacare.16.9.1296]

4 **Marks WM**, Filly RA, Callen PW. Ultrasonic evaluation of normal pancreatic echogenicity and its relationship to fat deposition. *Radiology* 1980; **137**: 475-479 [PMID: 7433680 DOI: 10.1148/radiology.137.2.7433680]

5 **Raeder H**, Haldorsen IS, Ersland L, Grüner R, Taxt T, Søvik O, Molven A, Njølstad PR. Pancreatic lipomatosis is a structural marker in nondiabetic children with mutations in carboxyl-ester lipase. *Diabetes* 2007; **56**: 444-449 [PMID: 17259390 DOI: 10.2337/db06-0859]

6 **Al-Haddad M**, Khashab M, Zyromski N, Pungpapong S, Wallace MB, Scolapio J, Woodward T, Noh K, Raimondo M. Risk factors for hyperechogenic pancreas on endoscopic ultrasound: a case-control study. *Pancreas* 2009; **38**: 672-675 [PMID: 19506531 DOI: 10.1097/MPA.0b013e3181a9d5af]

7 **Sepe PS**, Ohri A, Sanaka S, Berzin TM, Sekhon S, Bennett G, Mehta G, Chuttani R, Kane R, Pleskow D, Sawhney MS. A prospective evaluation of fatty pancreas by using EUS. *Gastrointest Endosc* 2011; **73**: 987-993 [PMID: 21521567 DOI: 10.1016/j.gie.2011.01.015]

8 **Lee JS**, Kim SH, Jun DW, Han JH, Jang EC, Park JY, Son BK, Kim SH, Jo YJ, Park YS, Kim YS. Clinical implications of fatty pancreas: correlations between fatty pancreas and metabolic syndrome. *World J Gastroenterol* 2009; **15**: 1869-1875 [PMID: 19370785 DOI: 10.3748/wjg.15.1869]

9 **Matsuzawa Y**. The metabolic syndrome and adipocytokines. *FEBS Lett* 2006; **580**: 2917-2921 [PMID: 16674947 DOI: 10.1016/j.febslet.2006.04.028]

10 **Arita Y**, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. *Biochem Biophys Res Commun* 1999; **257**: 79-83 [PMID: 10092513 DOI: 10.1006/bbrc.1999.0255]

11 **Hotta K**, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T, Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T, Matsuzawa Y. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. *Arterioscler Thromb Vasc Biol* 2000; **20**: 1595-1599 [PMID: 10845877 DOI: 10.1161/01.ATV.20.6.1595]

12 **Otake S**, Takeda H, Suzuki Y, Fukui T, Watanabe S, Ishihama K, Saito T, Togashi H, Nakamura T, Matsuzawa Y, Kawata S. Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma: evidence for participation of insulin resistance. *Clin Cancer Res* 2005; **11**: 3642-3646 [PMID: 15897559 DOI: 10.1158/1078-0432.CCR-04-1868]

13 **Otake S**, Takeda H, Fujishima S, Fukui T, Orii T, Sato T, Sasaki Y, Nishise S, Kawata S. Decreased levels of plasma adiponectin associated with increased risk of colorectal cancer. *World J Gastroenterol* 2010; **16**: 1252-1257 [PMID: 20222170 DOI: 10.3748/WJG.v16.i10.1252]

14 **Konta T**, Hao Z, Abiko H, Ishikawa M, Takahashi T, Ikeda A, Ichikawa K, Takasaki S, Kubota I. Prevalence and risk factor analysis of microalbuminuria in Japanese general population: the Takahata study. *Kidney Int* 2006; **70**: 751-756 [PMID: 16807548 DOI: 10.1038/sj.ki.5001504]

15 **Genuth S**, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P. Follow-up report on the diagnosis of diabetes mellitus. *Diabetes Care* 2003; **26**: 3160-3167 [PMID: 14578255 DOI: 10.2337/diacare.26.11.3160]

16 **Olsen TS**. Lipomatosis of the pancreas in autopsy material and its relation to age and overweight. *Acta Pathol Microbiol Scand A* 1978; **86A**: 367-373 [PMID: 716899 DOI: 10.1111/j.1699-0463.1978.tb02058.x]

17 **Schmitz-Moormann P**, Pittner PM, Heinze W. Lipomatosis of the pancreas. A morphometrical investigation. *Pathol Res Pract* 1981; **173**: 45-53 [PMID: 7335549 DOI: 10.1016/S0344-0338(81)80006-4]

18 **Matsumoto S**, Mori H, Miyake H, Takaki H, Maeda T, Yamada Y, Oga M. Uneven fatty replacement of the pancreas: evaluation with CT. *Radiology* 1995; **194**: 453-458 [PMID: 7824726 DOI: 10.1148/radiology.194.2.7824726]

19 **Lingvay I**, Esser V, Legendre JL, Price AL, Wertz KM, Adams-Huet B, Zhang S, Unger RH, Szczepaniak LS. Noninvasive quantification of pancreatic fat in humans. *J Clin Endocrinol Metab* 2009; **94**: 4070-4076 [PMID: 19773401 DOI: 10.1210/jc.2009-0584]

20 **Tushuizen ME**, Bunck MC, Pouwels PJ, Bontemps S, van Waesberghe JH, Schindhelm RK, Mari A, Heine RJ, Diamant M. Pancreatic fat content and beta-cell function in men with and without type 2 diabetes. *Diabetes Care* 2007; **30**: 2916-2921 [PMID: 17666465 DOI: 10.2337/dc07-0326]

21 **Matsuda A**, Makino N, Tozawa T, Shirahata N, Honda T, Ikeda Y, Sato H, Ito M, Kakizaki Y, Akamatsu M, Ueno Y, Kawata S. Pancreatic fat accumulation, fibrosis, and acinar cell injury in the Zucker diabetic fatty rat fed a chronic high-fat diet. *Pancreas* 2014; **43**: 735-743 [PMID: 24717823 DOI: 10.1097/MPA.0000000000000129]

**P-Reviewer:** Tretjakovs P **S-Editor:** Qi Y **L-Editor: E-Editor:**

**Table 1 Comparison of baseline characteristics between the pancreatic hyperechogenicity and control groups**

|  |  |  |  |
| --- | --- | --- | --- |
| **Clinical parameters** | **Pancreatic  hyperechogenicity**  **(*n* = 208)** | **Controls**  **(*n* = 264)** | ***P* value** |
| Age (yr) | 60.8 ± 9.4 | 56.9 ± 9.8 | < 0.001 |
| Fatty liver (fatty / non-fatty) | 113 / 95 | 93 / 171 | < 0.001 |
| Sex (male / female) | 86 / 122 | 115 / 149 | 0.640 |
| Height (cm) | 157.9 ± 8.4 | 159.3 ± 8.8 | 0.085 |
| Weight (kg) | 61.2 ± 9.4 | 56.2 ± 9.3 | < 0.001 |
| BMI (kg/m2) | 24.4 ± 2.6 | 22.1 ± 2.7 | < 0.001 |
| Systolic BP (mmHg) | 135.9 ± 15.8 | 129.6 ± 15.7 | < 0.001 |
| Diastolic BP (mmHg) | 83.1 ± 10.2 | 79.6 ± 10.2 | <0.001 |
| Adiponectin (μg/mL) | 8.9 (6.5 - 12.8) | 11.1 (7.8 -15.9) | < 0.001 |
| Serum insulin (μU/mL) | 4.7 (3.4 - 6.8) | 3.6 (2.7-5.0) | < 0.001 |
| Fasting plasma glucose (mg/dL) | 94.5 ± 9.2 | 90.8 ± 9.7 | < 0.001 |
| HOMA-IR | 1.1 (0.7 -1.6) | 0.8 (0.6 - 1.1) | < 0.001 |
| High-density lipoprotein cholesterol (mg/dL) | 58.4 ± 14.2 | 63.2 ± 15.4 | 0.001 |
| Low-density lipoprotein cholesterol (mg/dL) | 127.1 ± 36.1 | 123.8 ± 32.4 | 0.310 |
| Total cholesterol (mg/dL) | 205.9 ± 33.1 | 199.8 ± 34.4 | 0.049 |
| Triglyceride (mg/dL) | 96 (71 - 135) | 81 (63 - 112) | ＜0.001 |
| Pancreatic isoamylase (U/L) | 28 (23 - 34) | 30 (25 - 37) | 0.014 |
| Glutamic oxaloacetic transaminase (IU/L) | 23 (20- 27) | 22 (19- 28) | 0.706 |
| Glutamic pyruvic transaminase (IU/L) | 21 (17 -28) | 20 (15 -26) | 0.011 |
| γ-glutamyl transpeptidase (IU/L) | 24 (17 -42) | 22 (15-33) | 0.070 |
| Preload plasma glucose (OGTT) (mg/dL) | 97.4 ± 9.9 | 93.1 ± 10.2 | ＜0.001 |
| 2-h plasma glucose (OGTT) (mg/dL) | 114.6 ± 29.7 | 101.1 ± 26.7 | ＜0.001 |

Data are expressed as means ± SD, or median (25th; 75th percentiles). Unpaired *t* test or Fisher’s exact test were used to compare the two groups. BMI: Body mass index; BP: Blood pressure; HOMA-IR: Homeostasis model assessment of insulin resistance; OGTT: Oral glucose tolerance test.

**Table 2 Age-adjusted and multivariate odds ratios for pancreatic hyperechogenicity**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Confounding factor** | **Pancreatic  hyperechogenicity (*n*)** | **Controls**  **(*n*)** | **Age-adjusted** | | **Multivariate c** | |
| **Odds ratio**  **(95%CI)** | ***P* value** | **Odds ratio**  **(95%CI)** | ***P* value** |
| Non-fatty liver/ Fatty liver | 95/113 | 171/93 | 2.6 (1.8–3.9) | ＜0.001 | 1.77 (1.15 – 2.72) | 0.009 |
| BMI (kg/m2), < 25/≥ 25 | 125/83 | 229/35 | 5.0 (3.1–8.0) | ＜0.001 | 3.56 (2.17 – 5.83) | ＜0.001 |
| Systolic BP (mmHg), < 130/≥ 130 | 60/148 | 119/145 | 1.6 (1.1–2.5) | 0.016 |  |  |
| Diastolic BP (mmHg), < 85/≥ 85 | 110/98 | 180/84 | 1.9 (1.3–2.7) | 0.001 |  |  |
| Adiponectin (μg/mL)1 |  |  | 0.92 (0.88–0.95) | ＜0.001 | 0.9 (0.91 – 0.98) | 0.004 |
| Serum insulin (μU/mL)2, ≤ 4.0/> 4.0 | 83/125 | 153/111 | 2.2 (1.5–3.2) | ＜0.001 |  |  |
| Fasting plasma glucose (mg/dL), < 110/≥ 110 | 198/10 | 251/13 | 0.8 (0.3–1.9) | 0.593 |  |  |
| HOMA-IR, < 2.0/≥ 2.0 | 177/31 | 253/11 | 4.4 (2.1–9.1) | ＜0.001 | 2.4 (1.1 – 5.1) | 0.032 |
| HDL cholesterol (mg/dL), ≥ 40/< 40 | 194/14 | 253/11 | 1.9 (0.8–4.5) | 0.119 |  |  |
| Triglyceride (mg/dL), < 150/≥ 150 | 173/35 | 234/30 | 1.7 (1.0–2.9) | 0.055 |  |  |
| Pancreatic isoamylase (U/l)2, ≥ 30/< 30 | 89/119 | 143/121 | 1.7 (1.2–2.5) | 0.004 | 2.08 (0.95 – 4.57) | 0.068 |
| GPT (IU/L), < 35/≥ 35 | 177/31 | 234/30 | 1.7 (1.0–2.9) | 0.069 |  |  |
| Preload plasma glucose (OGTT) (mg/dl), < 110/≥ 110 | 189/19 | 247/17 | 1.1 (0.6–2.3) | 0.710 |  |  |
| 2-h plasma glucose (OGTT) (mg/dL), < 140/≥ 140 | 170/38 | 244/20 | 2.4 (1.3–4.3) | 0.003 |  |  |
| 1Serum adiponectin was analyzed as a continuous variable. 2The median values for serum insulin and pancreatic isoamylase were used as the cutoff points;3Adjusted for the age, presence of fatty liver, BMI, systolic BP, diastolic BP, adiponectin, serum insulin, HOMA-IR, triglyceride, pancreatic isoamylase, GPT and 2-h plasma glucose. Odds ratios and 95%CI were estimated using the multiple logistic regression model with backward elimination. BMI: Body mass index; BP: Blood pressure; HOMA-IR: Homeostasis model assessment of insulin resistance; HDL: High-density lipoprotein; GPT: Glutamic pyruvic transaminase; OGTT: Oral glucose tolerance test. | | | | | | |

**Table 3 Comparison of baseline characteristics between the pancreatic hyperechogenicity and control groups excluding participants with fatty liver**

|  |  |  |  |
| --- | --- | --- | --- |
| **Clinical parameters** | **Pancreatic  hyperechogenicity**  **(*n* = 95)** | **Control**  **(*n* = 171)** | ***P* value** |
| Age (yr) | 62 ± 9 | 58 ± 10 | 0.001 |
| Sex (male / female) | 44 / 51 | 76 / 95 | 0.769 |
| Height (cm) | 158.0 ± 8.0 | 158.1 ± 9.0 | 0.960 |
| Weight (kg) | 59.5 ± 9.4 | 53.9 ± 8.5 | < 0.001 |
| BMI (kg/m2) | 23.7 ± 2.6 | 21.5 ± 2.5 | < 0.001 |
| Systolic BP (mm Hg) | 133 ± 17 | 130 ± 16 | 0.135 |
| Diastolic BP (mm Hg) | 82 ± 11 | 80 ± 10 | 0.180 |
| Adiponectin (μg/mL) | 10.3 (7.6 -14.6) | 12.0 (8.6-17.0) | 0.022 |
| Serum insulin (μU/mL) | 4.0 (2.7-5.4) | 3.3 (2.5- 4.5) | 0.004 |
| Fasting plasma glucose (mg/dL) | 93 ± 8 | 90 ± 10 | 0.026 |
| HOMA-IR | 0.9 (0.59- 1.28) | 0.71 (0.54 -1.02) | 0.002 |
| High-density lipoprotein cholesterol (mg/dL) | 60 ± 15 | 66 ± 15 | 0.001 |
| Low-density lipoprotein cholesterol (mg/dL) | 124 ± 35 | 122 ± 33 | 0.708 |
| Total cholesterol (mg/dL) | 202 ± 33 | 199 ± 36 | 0.464 |
| Triglyceride (mg/dL) | 87 (66-133) | 76 (59 - 96) | 0.005 |
| Pancreatic isoamylase (U/L) | 29 (24 -35) | 31 (25- 37) | 0.054 |
| Glutamic oxaloacetic transaminase (IU/L) | 22 (19 - 25) | 23 (19 -28) | 0.189 |
| Glutamic pyruvic transaminase (IU/L) | 19 (16- 23) | 20 (15 -25) | 0.937 |
| γ-glutamyl transpeptidase (IU/L) | 21 (16 - 40) | 21 (15- 32) | 0.266 |
| Preload plasma glucose (OGTT) (mg/dL) | 96 ± 9 | 92 ± 10 | 0.009 |
| 2-h plasma glucose (OGTT) (mg/dL) | 107 ± 29 | 100 ± 28 | 0.063 |
| Data are expressed as means ± SD, or median (25th; 75th percentiles). Unpaired *t* test or Fisher’s exact test were used to compare the two groups. BMI: Body mass index; BP: Blood pressure; HOMA-IR: Homeostasis model assessment of insulin resistance; OGTT: Oral glucose tolerance test. | | | |

**Table 4 Multivariate association analysis of clinical parameters for pancreatic hyperechogenicity excluding participants with fatty liver**

|  |  |  |
| --- | --- | --- |
|  | **Multivariate2** | |
| **Confounding factor** | **Odds ratio (95%CI)** | ***P* value** |
| BMI (kg/m2) | 3.89 (2.39 – 6.35) | < 0.001 |
| Adiponectin (μg/mL)1 | 0.93 (0.90 – 0.97) | < 0.001 |
| HOMA-IR | 2.23 (1.02 – 4.89) | 0.045 |

1Serum adiponectin was analyzed as a continuous variable; 2Adjusted for age, BMI, diastolic BP, adiponectin, serum insulin, HOMA-IR, HDL cholesterol, triglyceride and pancreatic isoamylase. Odds ratios and 95%CI were estimated using the multiple logistic regression model with backward elimination. CI: Confidence interval; BMI: Body mass index; HOMA-IR: Homeostasis model assessment of insulin resistance.